Brian DiCarlo

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 276 citations · Full text

First-line Therapy, Gastrointestinal Oncology, Medicine +6

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction

Z.A. Wainberg, L. S. Lin, Brian DiCarlo et al. · British Journal of Cancer · 2011 · 83 citations · Full text

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Sara A. Hurvitz, Jennifer L. Caswell‐Jin, Katherine McNamara et al. · Nature Communications · 2020 · 63 citations · Full text

TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.

Sara A. Hurvitz, Lisa S. Wang, David W. Chan et al. · Journal of Clinical Oncology · 2022 · 37 citations

Breast Oncology, Tps623 Background, Medicine +15

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

Sara A. Hurvitz, Rashi Singh, Brad Adams et al. · Therapeutic Advances in Medical Oncology · 2018 · 30 citations · Full text